Bincy P. Abraham, MD

Fondren Distinguished Professor in Inflammatory Bowel Disease, Department of Medicine
Associate Professor of Clinical Medicine, Academic Institute
Associate Clinical Member, Research Institute
Program Director, Gastroenterology Fellowship Program, Lynda K. and David M. Underwood Center for Digestive Disorders
Houston Methodist
Weill Cornell Medical College


Bincy P. Abraham, MD, MS, is an associate professor of clinical medicine in the Academic Division of Gastroenterology and Hepatology at Houston Methodist – Weill Cornell in Houston, Texas.

Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation of America at Cedars-Sinai Medical Center in Los Angeles, California. She is board certified in Internal medicine and Gastroenterology. Dr. Abraham is a member of the American Gastroenterological Association, American College of Gastroenterology, Crohn’s and Colitis Foundation, American Society of Gastrointestinal Endoscopy, and chair of the South Texas Chapter of the Crohn’s and Colitis Foundation Medical Advisory Committee.

Description of Research

Dr. Abraham is a principal investigator and coinvestigator in several key clinical trials. As author or coauthor, Dr. Abraham’s work has been published in peer-reviewed medical journals including Clinical Gastroenterology and Hepatology, American Journal of Gastroenterology, and Inflammatory Bowel Diseases.

Areas Of Expertise

Crohn's disease Pregnancy & inflammatory bowel disease Transition of care in inflammatory bowel disease Ulcerative colitis

Nanotechnology in the Treatment of Inflammatory Bowel Disease
Giron, F, Pastó, A, Tasciotti, E & Abraham, BP 2019, Inflammatory bowel diseases, vol. 25, no. 12, pp. 1871-1880.

Antibiotics and probiotics in inflammatory bowel disease: When to use them?
Abraham, BP & Quigley, EM 2019, Frontline Gastroenterology.

Fecal lactoferrin testing
Abraham, BP 2018, Gastroenterology and Hepatology, vol. 14, no. 12, pp. 713-716.

Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis
Clinical Research Alliance of the Crohns and Colitis Foundation 2018, Gastroenterology, vol. 155, no. 4, pp. 1098-1108.e9.

A Probiotic for Ulcerative Colitis: The Culture Wars Continue
Abraham, BP & Quigley, EM 2018, Digestive Diseases and Sciences, pp. 1-3.

Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study
Mariette, X, Förger, F, Abraham, BP, Flynn, AD, Moltó, A, Flipo, RM, Van Tubergen, A, Shaughnessy, L, Simpson, J, Teil, M, Helmer, E, Wang, M & Chakravarty, EF 2018, Annals of the Rheumatic Diseases, vol. 77, no. 2, pp. 228-233.

Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases
Corbo, C, Cromer, WE, Molinaro, R, Toledano Furman, NE, Hartman, KA, De Rosa, E, Boada, C, Wang, X, Zawieja, DC, Agostini, M, Salvatore, F, Abraham, BP & Tasciotti, E 2017, Nanoscale.

Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease
Sandborn, WJ, Wolf, DC, Kosutic, G, Parker, G, Schreiber, S, Lee, SD, Abraham, B, Afzali, A, Arsenescu, RI, Gutierrez, A, Spearman, M, Coarse, J & Feagan, BG 2017, Inflammatory Bowel Diseases, vol. 23, no. 7, pp. 1047-1056.

Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease among Patients with Inflammatory Bowel Disease
Glassner, K, Malaty, HM & Abraham, BP 2017, Inflammatory Bowel Diseases, vol. 23, no. 6, pp. 998-1003.

Polymorphisms of 5-HTT LPR and GNß3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial
Saito, YA, Locke, GR, Almazar, AE, Bouras, EP, Howden, CW, Lacy, BE, DiBaise, JK, Prather, CM, Abraham, BP, El-Serag, HB, Moayyedi, P, Herrick, LM, Szarka, LA, Camilleri, M, Hamilton, FA, Schleck, CD, Tilkes, KE, Zinsmeister, AR & Talley, NJ 2017, American Journal of Gastroenterology.

Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches
Abraham, BP, Ahmed, T & Ali, T 2017, . in B Greenwood-Van Meerveld (ed.), Gastrointestinal Pharmacology. vol. 239, Handbook of Experimental Pharmacology, vol. 239, Springer, pp. 115-146.

Probiotics in Inflammatory Bowel Disease
Abraham, BP & Quigley, EMM 2017, Gastroenterology Clinics of North America.

Ustekinumab as induction and maintenance therapy for Crohn's disease
UNITI-IM-UNITI Study Group 2016, New England Journal of Medicine, vol. 375, no. 20, pp. 1946-1960.

The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease
Koduru, P & Abraham, BP 2016, Therapeutic Advances in Gastroenterology, vol. 9, no. 1, pp. 76-85.

Cancer surveillance in ulcerative colitis and Crohn's disease: New strategies
Abraham, BP 2016, Current Opinion in Gastroenterology, vol. 32, no. 1, pp. 32-7.

Symptom management in inflammatory bowel disease
Abraham, BP 2015, Expert Review of Gastroenterology and Hepatology, vol. 9, no. 7, pp. 953-967.

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: Analyses from the 7-year PRECiSE 3 study
Sandborn, WJ, Melmed, GY, McGovern, DPB, Loftus, EV, Choi, JM, Cho, JH, Abraham, B, Gutierrez, A, Lichtenstein, G, Lee, SD, Randall, CW, Schwartz, DA, Regueiro, M, Siegel, CA, Spearman, M, Kosutic, G, Pierre-Louis, B, Coarse, J & Schreiber, S 2015, Alimentary Pharmacology and Therapeutics, vol. 42, no. 3, pp. 330-342.

Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study
Melmed, GY, Pandak, WM, Casey, K, Abraham, B, Valentine, J, Schwartz, D, Awais, D, Bassan, I, Lichtiger, S, Sands, B, Hanauer, S, Richards, R, Oikonomou, I, Parekh, N, Targan, S, Johnson, K, Hariri, R & Fischkoff, S 2015, Inflammatory Bowel Diseases, vol. 21, no. 8, pp. 1809-16.

Effect of amitriptyline and escitalopram on functional dyspepsia: A multicenter, randomized controlled study
Talley, NJ, Richard Locke, G, Saito, YA, Almazar, AE, Bouras, EP, Howden, CW, Lacy, BE, Dibaise, JK, Prather, CM, Abraham, BP, El-Serag, HB, Moayyedi, P, Herrick, LM, Szarka, LA, Camilleri, M, Hamilton, FA, Schleck, CD, Tilkes, KE & Zinsmeister, AR 2015, Gastroenterology, vol. 149, no. 2, pp. 340-349.e2.

Medical and Surgical Complications of Inflammatory Bowel Disease in the Elderly: A Systematic Review
Shung, DL, Abraham, BP, Sellin, J & Hou, JK 2015, Digestive Diseases and Sciences, vol. 60, no. 5, pp. 1132-1140.

Live Chat Available